FY2030 Earnings Estimate for Savara Issued By HC Wainwright

Savara Inc. (NASDAQ:SVRA) – Investment analysts at HC Wainwright issued their FY2030 EPS estimates for shares of Savara in a research report issued to clients and investors on Monday, March 9th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of $0.91 per share for the year. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share.

Other analysts have also issued research reports about the company. Oppenheimer set a $10.00 price objective on Savara in a report on Tuesday, December 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research note on Thursday, January 22nd. Guggenheim reiterated a “buy” rating on shares of Savara in a research note on Tuesday, December 23rd. UBS Group set a $10.00 price target on Savara in a report on Tuesday, December 23rd. Finally, Wells Fargo & Company upped their price objective on shares of Savara from $7.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $8.86.

Savara Price Performance

Shares of SVRA opened at $5.53 on Wednesday. The company has a 50 day moving average of $5.69 and a two-hundred day moving average of $4.93. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.32. Savara has a twelve month low of $1.89 and a twelve month high of $7.01. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -10.43 and a beta of 0.31.

Institutional Trading of Savara

Large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Savara by 48.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock valued at $60,000 after purchasing an additional 3,205 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Savara by 930.5% during the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after purchasing an additional 9,463 shares during the period. Xponance LLC purchased a new stake in Savara in the fourth quarter valued at approximately $66,000. CIBC Bancorp USA Inc. purchased a new stake in Savara in the third quarter valued at approximately $44,000. Finally, Prudential Financial Inc. acquired a new position in Savara in the 2nd quarter worth approximately $30,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.